Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
NCT05366829 is a phase 2 interventional trial sponsored by Rutgers, The State University of New Jersey. As of 21 Nov 2026, it is recruiting participants. It studies Tislelizumab in Carcinoma, Hepatocellular and Liver Cell Carcinoma. The registry lists an enrollment of 35 participants at 2 sites in 1 country. The registry lists a start date of 25 Jul 2022 and a primary completion date of 1 Jun 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05366829 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Rutgers, The State University of New Jersey |
| Enrollment | 35 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Carcinoma, Hepatocellular and Liver Cell Carcinoma |
| Drugs | Tislelizumab |
| Start | 25 Jul 2022 |
| Primary completion | 1 Jun 2027 |
| Study completion | 1 Jun 2027 |
| Last update posted | 20 Jan 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rutgers Cancer Institute of New Jersey
New Brunswick
Recruiting
- Montefiore Medical Center
The Bronx
Recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05366829
Each answer restates registry values shown on this page.
What is NCT05366829?
NCT05366829 is a phase 2 interventional trial sponsored by Rutgers, The State University of New Jersey. It studies Tislelizumab in Carcinoma, Hepatocellular and Liver Cell Carcinoma.
Is NCT05366829 recruiting?
As of 21 Nov 2026, it is recruiting participants. 2 of its 2 sites list their own status as recruiting.
Who leads NCT05366829?
The registry names Salma Jabbour, MD (principal investigator, Rutgers Cancer Institute of New Jersey) as the overall official.
Where does NCT05366829 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05366829 study?
The registered drug and biological interventions are Tislelizumab.
When is NCT05366829 expected to complete?
The registry lists a primary completion date of 1 Jun 2027 and a study completion date of 1 Jun 2027. The sponsor last updated the record on 20 Jan 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.